Shutterstock.com

Lawmakers Press the Trump Administration for More Transparency on Coronavirus Drug Distribution

Inquiry comes after reports of a chaotic initial rollout.

Lawmakers are pressing the Trump administration for data about how officials are distributing remdesivir, the only drug approved thus far to treat the novel coronavirus. 

Since the Food and Drug Administration issued emergency use authorization for the drug on May 1, doctors, hospitals and lawmakers have been raising questions about where the much sought after drug is going and based on what criteria. On Wednesday, 13 Senators—one Independent and 12 Democrats—asked Health and Human Services Secretary Alex Azar to explain how the federal government is distributing the drug. 

“We acknowledge that the limited current supply and substantial demand for remdesivir results in necessary choices about distribution. However, in the midst of this pandemic, it is unacceptable for our health care system and patients to be left in the dark,” the lawmakers wrote. “Given the likelihood of future therapeutics and vaccines being approved or authorized for use in the U.S., it is essential that the administration assuage concerns about this initial test run of such federal distribution.” 

Doctors and hospitals nationwide criticized the administration’s “uneven and opaque” way of initially distributing remdesivir, Stat News reported on May 6. Clinicians told the outlet they were not sure why some medical facilities were selected to receive the drug while others were not. 

On May 11, The Wall Street Journal reported that Dr. Deborah Birx, White House coronavirus response coordinator, said in an email on May 7 that the administration’s initial distribution of remdesivir was flawed. “Hospitals were told they would be notified directly by AmerisourceBergen Corp., a drug wholesaler that is distributing the drug on behalf of the federal government, if they were chosen to receive remdesivir,” said the paper. “Hospitals said they were not informed why certain hospitals were chosen and others weren’t, and complained that shipments were failing to reach those who needed the drug most.” 

Two days after Birx reportedly sent the email to coronavirus task force members, the Health and Human Services Department issued a statement saying that states will now get the drug and then distribute it to hospitals based on their needs.

“With a sense of urgency to get doses to hospitalized patients, it has been determined that state health departments have the greatest insight into which hospitals in their states have the greatest number of COVID-19 patients meeting the criteria for use of remdesivir under the Emergency Use Authorization,” a HHS spokesperson told Government Executive on Thursday. “State health departments have worked with hospitals on strategies for caring for COVID-19 patients within their states, and will be working with hospitals on distribution of the limited supply of donated remdesivir. Gilead is using its distributor to deliver the donated remdesivir to state health departments.”

The senators asked Azar for a briefing by May 19 from administration officials involved in the allocation process to “ensure equitable distribution” of the drug. They also asked for the relevant agencies to create a public-facing portal to showcase their selection methodology and establish a process for hospitals to request remdesivir. The $2.2 trillion CARES Act, enacted in late March, provided funding to address drug supply shortages and expedite the approval process. 

“We have received a number of letters from Congress on COVID-19, and the department is working to respond,” said the HHS spokesperson. “We continue to maintain an open line of communication with members of Congress, including briefings for members of both the House and Senate, while helping coordinate the response to the public health emergency.”

The distribution of remdesivir also came up during Dr. Rick Bright’s testimony before a House subcommittee on Thursday. Bright, who was ousted from his position as director of the Biomedical Advanced Research and Development Authority in April, filed a whistleblower complaint with the Office of Special Counsel that alleged, among other things, he was involuntarily transferred to a lower position following his protected disclosures about the administration's push to use an unproven malaria-drug to treat the coronavirus. 

Rep. Raul Ruiz, D-Calif., noted that in his complaint, Bright warned about potential shortages of remdesivir over three months ago following preliminary reports that the drug could help patients recover from coronavirus. 

“We would have had a plan,” said Bright, when asked if he thinks the transparency issues could have been avoided if HHS officials listened to him. “We should have had a plan for that drug and any other drug in limited supply.” 

X
This website uses cookies to enhance user experience and to analyze performance and traffic on our website. We also share information about your use of our site with our social media, advertising and analytics partners. Learn More / Do Not Sell My Personal Information
Accept Cookies
X
Cookie Preferences Cookie List

Do Not Sell My Personal Information

When you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer. Click on the different category headings to find out more and change our default settings according to your preference. You cannot opt-out of our First Party Strictly Necessary Cookies as they are deployed in order to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information about the First and Third Party Cookies used please follow this link.

Allow All Cookies

Manage Consent Preferences

Strictly Necessary Cookies - Always Active

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Sale of Personal Data, Targeting & Social Media Cookies

Under the California Consumer Privacy Act, you have the right to opt-out of the sale of your personal information to third parties. These cookies collect information for analytics and to personalize your experience with targeted ads. You may exercise your right to opt out of the sale of personal information by using this toggle switch. If you opt out we will not be able to offer you personalised ads and will not hand over your personal information to any third parties. Additionally, you may contact our legal department for further clarification about your rights as a California consumer by using this Exercise My Rights link

If you have enabled privacy controls on your browser (such as a plugin), we have to take that as a valid request to opt-out. Therefore we would not be able to track your activity through the web. This may affect our ability to personalize ads according to your preferences.

Targeting cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Social media cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your browser across other sites and building up a profile of your interests. This may impact the content and messages you see on other websites you visit. If you do not allow these cookies you may not be able to use or see these sharing tools.

If you want to opt out of all of our lead reports and lists, please submit a privacy request at our Do Not Sell page.

Save Settings
Cookie Preferences Cookie List

Cookie List

A cookie is a small piece of data (text file) that a website – when visited by a user – asks your browser to store on your device in order to remember information about you, such as your language preference or login information. Those cookies are set by us and called first-party cookies. We also use third-party cookies – which are cookies from a domain different than the domain of the website you are visiting – for our advertising and marketing efforts. More specifically, we use cookies and other tracking technologies for the following purposes:

Strictly Necessary Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Functional Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Performance Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Sale of Personal Data

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Social Media Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Targeting Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.